Abstract: A culture vessel that can suppress foaming in a culture medium when a common nozzle is used to supply a liquid culture medium and a gas together. This culture vessel includes: a vessel body having an opening portion that communicates with a housing space; a lid that closes the opening portion; and a nozzle that passes through the and extends to the housing space, and supplies a liquid culture medium and a gas together. The nozzle has a vent opening portion that is formed so as to open in a side of the nozzle and serves as a movement path of the gas from inside of the nozzle into the housing space.

Abstract: Provided are a novel evaluation system and an evaluation method for evaluating a state of cells. The evaluation system includes: a Raman spectroscopic device configured to perform Raman spectroscopic analysis on extracellular vesicles contained in a culture supernatant of the cells; and an analysis device configured to evaluate the state of the cells based on a Raman spectrum obtained by the Raman spectroscopic analysis.

Abstract: A liquid feed device that feeds a liquid medium and a cell suspension to target containers by respectively suited liquid feed methods is provided. A pump 6 is connected between a first liquid bottle 12 containing a liquid medium and a second liquid bottle 2 containing a cell suspension, and a receptacle 8 to be used as a culture container is connected downstream of a second liquid bottle 12. The liquid medium in the first liquid bottle is sent to the receptacle through the pump 6 and a branch point 20 by opening a first supply valve 17, and the cell suspension in the second liquid bottle is sent to the receptacle by opening a first gas introducing valve 10, a second gas introducing valve 15, and a second supply valve 19 and transferring, by pressure, a gas supplied from the first gas introducing valve 10 to the second liquid bottle through the pump 6 and a branch point 16.

Abstract: Provided are an evaluator including an analysis unit that evaluates a differentiation level of a cultured cell on the basis of a content of a component in a culture supernatant of the cultured cell, and an automatic cell culture system including the evaluator and an automatic culture device.

Abstract: A liquid delivery device includes a first and second container for a first and second liquid; a third container for receiving a first and second liquid; a fourth container into which a first and second liquid are discharged; a fifth container for a third liquid; a first liquid delivery tube for delivering a first liquid; a second liquid delivery tube for delivering a second liquid; a third liquid delivery tube connected to the first and second liquid delivery tube; a first liquid delivery pump on the third liquid delivery tube; a fourth liquid delivery tube for discharging a first liquid contained in the third container and delivering a third liquid to the third container; a fifth liquid delivery tube connected to the fourth liquid delivery tube; a sixth liquid delivery tube connected to the fourth liquid delivery tube; and a second liquid delivery pump on the fourth liquid delivery tube.

Abstract: An object of the invention is to provide a cell culture monitoring device capable of monitoring the number of cells during culture and a cell culture system. The cell culture monitoring device for monitoring proliferation of cells includes: a detection unit configured to detect particles of exosomes in culture supernatant; and an analysis unit configured to calculate the number of cells based on an obtained detection result. The cell culture system includes the cell culture monitoring device and an automatic culture device.

Abstract: A culture vessel that can suppress foaming in a culture medium when a common nozzle is used to supply a liquid culture medium and a gas together. This culture vessel includes: a vessel body having an opening portion that communicates with a housing space; a lid that closes the opening portion; and a nozzle that passes through the and extends to the housing space, and supplies a liquid culture medium and a gas together. The nozzle has a vent opening portion that is formed so as to open in a side of the nozzle and serves as a movement path of the gas from inside of the nozzle into the housing space.

Abstract: A liquid feed device that feeds a liquid medium and a cell suspension to target containers by respectively suited liquid feed methods is provided. A pump 6 is connected between a first liquid bottle 12 containing a liquid medium and a second liquid bottle 2 containing a cell suspension, and a receptacle 8 to be used as a culture container is connected downstream of a second liquid bottle 12. The liquid medium in the first liquid bottle is sent to the receptacle through the pump 6 and a branch point 20 by opening a first supply valve 17, and the cell suspension in the second liquid bottle is sent to the receptacle by opening a first gas introducing valve 10, a second gas introducing valve 15, and a second supply valve 19 and transferring, by pressure, a gas supplied from the first gas introducing valve 10 to the second liquid bottle through the pump 6 and a branch point 16.

Abstract: A liquid delivery device includes a first and second container for a first and second liquid; a third container for receiving a first and second liquid; a fourth container into which a first and second liquid are discharged; a fifth container for a third liquid; a first liquid delivery tube for delivering a first liquid; a second liquid delivery tube for delivering a second liquid; a third liquid delivery tube connected to the first and second liquid delivery tube; a first liquid delivery pump on the third liquid delivery tube; a fourth liquid delivery tube for discharging a first liquid contained in the third container and delivering a third liquid to the third container; a fifth liquid delivery tube connected to the fourth liquid delivery tube; a sixth liquid delivery tube connected to the fourth liquid delivery tube; and a second liquid delivery pump on the fourth liquid delivery tube.

Abstract: A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.

Abstract: A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.

Abstract: Provided is a pharmaceutical composition for treating cancer and asthma. The object can be solved by a pharmaceutical composition comprising a siRNA molecule that directs cleavage of mRNA of mucin subtype 5 AC via RNA interference, or an antibody against mucin subtype 5AC as an active ingredient. According to the pharmaceutical composition of the present invention, diseases involving an overexpression of mucin subtype 5 AC can be treated efficiently. In particular, the pharmaceutical composition comprising a siRNA molecule of the present invention is effectively used in the treatment of a cancer, particularly pancreatic cancer. In addition, the siRNA or the antibody of the present invention can inhibit the expression or function of MUC5AC, thereby preventing or treating the symptoms of asthma effectively.

Abstract: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Abstract: An antibody which recognizes PSK is provided. The object of the present invention is solved by an antibody characterized by recognizing PSK and inhibiting anti-tumor activity of PSK. In particular, the inhibition of anti-tumor activity of PSK is an inhibition of cytotoxic activity or an inhibition of anti-TGF-?1 activity of PSK. A physiologically active PSK can, using the present invention, be detected high-accurately and quantitatively. For example, the present invention is useful for detecting and measuring the physiologically active PSK contained in a medicine or a food and drink, and for analyzing pharmacokinetics after administrating the physiologically active PSK.

Abstract: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Abstract: Provided is a pharmaceutical composition for treating cancer and asthma. The object can be solved by a pharmaceutical composition comprising a siRNA molecule that directs cleavage of mRNA of mucin subtype 5 AC via RNA interference, or an antibody against mucin subtype 5AC as an active ingredient. According to the pharmaceutical composition of the present invention, diseases involving an overexpression of mucin subtype 5 AC can be treated efficiently. In particular, the pharmaceutical composition comprising a siRNA molecule of the present invention is effectively used in the treatment of a cancer, particularly pancreatic cancer. In addition, the siRNA or the antibody of the present invention can inhibit the expression or function of MUC5AC, thereby preventing or treating the symptoms of asthma effectively.

Abstract: A portable personal server connectable through a network with a PC connected with an external network that permits communication with the PC only when user's fingerprint information read out by means of a fingerprint authentication unit matches registered information. In order to communicate through the network, the portable personal server and the PC acquires an address, preferably using APIPA, so that the collision of address does not take place in the external network. Consequently, the portable personal server also functions as a network server on the external network. A portable personal server exhibiting high confidentiality of data and suitable for central management of data can thereby be realized.

Abstract: An agent comprising, as an active ingredient, a xanthine oxidase inhibitor such as 2-[3-cyano-4-(4-fluorophenoxy)phenyl]-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-[3-cyano-4-(4-fluorophenoxy)phenyl]thiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine, 2-(3-cyano-4-phenoxyphenyl)-4-hydroxythiazolo[5,4-d]pyrimidine potassium salt, 2-(3-cyano-4-phenoxyphenyl)thiazolo[5,4-d]pyrimidine, TMX-67, and FYX-051, which can be used as an agent for overcoming anti-cancer agent resistance.

Abstract: A portable personal server connectable through a network with a PC connected with an external network that permits communication with the PC only when user's fingerprint information read out by means of a fingerprint authentication unit matches registered information. In order to communicate through the network, the portable personal server and the PC acquires an address, preferably using APIPA, so that the collision of address does not take place in the external network. Consequently, the portable personal server also functions as a network server on the external network. A portable personal server exhibiting high confidentiality of data and suitable for central management of data can thereby be realized.

Abstract: The communication terminal of a communication system comprises a virtual network switch which can forcibly alter the destination of data being transmitted/received between the communication terminal and a network. Data is transmitted/received between the network and the communication terminal through a portable electronic device. Various functions, including a security function, can be supplemented by providing the function in software mounted on the portable electronic device. Even if a communication terminal connected directly with the network is not provided with such functions as a VPN, firewall or virus check, high-safety communication is ensured utilizing these security ensuring means mounted on the portable electronic device.